Boston Scientific (NYSE:BSX) Reaches New 1-Year Low - Time to Sell?

Key Points

• Boston Scientific shares fell to a new 52-week low of $41.50, trading below both their 50-day ($46.72) and 200-day ($50.90) moving averages.
• Despite the decline, analysts remain broadly positive: 22 rate the stock a Buy, with a consensus “Moderate Buy” rating and a $66.31 target price, implying substantial upside.
• The company recently exceeded quarterly earnings and revenue expectations, with revenue up 7.5% year over year. Insiders have also bought roughly $9.4 million of shares over the past 90 days, while institutional investors own 89.07% of the stock.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) shares hit a new 52-week low on Thursday. The company traded as low as $41.50 and last traded at $41.5470, with a volume of 15871082 shares changing hands. The stock had previously closed at $42.19.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research analyst reports. Canaccord Genuity Group reduced their target price on Boston Scientific from $70.00 to $66.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Piper Sandler reissued an "overweight" rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Wells Fargo & Company reduced their price objective on Boston Scientific from $50.00 to $48.00 and set an "equal weight" rating for the company in a research note on Wednesday, September 23rd. Leerink Partners set a $60.00 target price on Boston Scientific in a report on Thursday, July 30th. Finally, TD Cowen reiterated a "buy" rating on shares of Boston Scientific in a research report on Thursday, September 17th. Twenty-two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.31.

Boston Scientific Stock Performance

The firm's fifty day simple moving average is $46.72 and its 200 day simple moving average is $50.90. The company has a market capitalization of $60.21 billion, a PE ratio of 16.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company's revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.25 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, Director David Habiger acquired 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company's stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Edward Ludwig bought 5,000 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently modified their holdings of BSX. South Plains Financial Inc. purchased a new position in shares of Boston Scientific during the 4th quarter valued at approximately $39,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the first quarter worth $28,000. Cassaday & Co Wealth Management LLC acquired a new position in Boston Scientific during the first quarter worth $32,000. Measured Wealth Private Client Group LLC lifted its holdings in Boston Scientific by 244.9% during the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 387 shares in the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $54,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.